Arrowhead Names Daniel Apel as New CFO

Arrowhead Pharmaceuticals announced that CFO Ken Myszkowski will retire on May 13, 2025, after 16 years. He will be succeeded by Daniel Apel, a former executive at Walgreens and Bayer. Myszkowski will remain as an adviser during the transition. The move comes as Arrowhead prepares for the potential launch of plozasiran.